Ambrisentan for treatment of inoperable chronic thromboembolic pulmonary hypertension (CTEPH)

This multicenter, randomized, double-blind, placebo-controlled study assessed ambrisentan or placebo in patients with inoperable chronic thromboembolic pulmonary hypertension. Futility of enrollment led to early termination. Trends of improvement in favor of ambrisentan versus placebo in the primary...

Descripción completa

Detalles Bibliográficos
Autores principales: Escribano-Subias, Pilar, Bendjenana, Hakim, Curtis, Paula S., Lang, Irene, Noordegraaf, Anton Vonk
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2019
Materias:
Research Letter
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6540507/
https://www.ncbi.nlm.nih.gov/pubmed/30957635
http://dx.doi.org/10.1177/2045894019846433

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6540507/
https://www.ncbi.nlm.nih.gov/pubmed/30957635
http://dx.doi.org/10.1177/2045894019846433

Ejemplares similares